The glycosaminoglycans of human cultured normal glial and malignant glioma cells were studied.
In normal cultures the glycosaminoglycans of the pericellular pool (trypsin-susceptible material), the membrane fraction (trypsin-susceptible material of EDTA-detached cells) and the substrate-attached material consisted mainly of heparan sulphate. The iditra-and extra-cellular pools showed a predominance of dermatan sulphate. The net production of hyaluronic acid was low. The accumulation of 35S-labelled glycosaminoglycans in the extracellular pool was essentially linear with time up to 72h. The malignant glioma cells differed in most aspects tested. The total production of glycosaminoglycans was much greater owing to a high production of hyaluronic acid and hyaluronic acid was the major cell-surface-associated glycosaminoglycan in these cultures. Among the sulphated glycosaminoglycans chondroitin sulphate, rather than heparan sulphate, was the predominant species of the pericellular pool. This was also true for the membrane fraction and substrate-attached material. Furthermore, the accumulation of extracellular 35S-labelled glycosaminoglycans was initially delayed for several hours and did not become linear with time until after 24h of incubation. The glioma cells produced little dermatan sulphate and the dermatan sulphate chains differed from those of normal cultures with respect to the distribution of iduronic acid residues. The observed differences between normal glial and malignant glioma cells were not dependent on cell density; rather they were due to the malignant transformation itself.
Most or all mammalian cells produce and metabolize glycosaminoglycans (Kraemer, 1972) . The widespread occurrence of this kind of substance indicates that they may have important biological functions. In particular, the localization of certain glycosaminoglycans in the plasma membrane may suggest their involvement in cellular interaction phenomena, e.g. between individual cells or between cells and compounds of the extracellular space. The possible role of glycosaminoglycans in cell biological phenomena has been studied in cell culture. In such systems, they may influence cell proliferation (see, e.g., Lippman, 1968; Ohnishi etal., 1975) , celladhesion (Roblin et al., 1975; Culp, 1976) or cell aggregation (Burger & Martin, 1972; Pessac & Defendi, 1972; Wasteson et al., 1973b) . Many studies dealing with glycosaminoglycans of various non-human, mostly
Vol. 172 rodent, cell lines have been published (see, e.g., Roblin et al., 1975 , and references quoted therein). In contrast, the structure and metabolism of glycosaminoglycans of human normal cells have only been studied in few types of cells, such investigations being almost exclusively limited to fibroblasts (Malmstrom et al., 1975; Kleinman et al., 1975) .
The importance of glycosaminoglycans in normal and malignant growth control is virtually unknown, although quantitative and qualitative differences in the production and composition of glycosaminoglycans have been revealed in certain virus-transformed cells, compared with their non-transformed counterparts (see, e.g., Cohn et al., 1976 , and references quoted therein). The importance of using a strictly normal cell as a reference (Ponten, 1975) in such studies does not seem to have been fully recognized. Also, more information is needed on human cell systems before general conclusions can be made.
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We have initiated an investigation on the structural and metabolic features of glycosaminoglycans produced by human normal and malignant cultured glial cells. By using this cell system strictly normal diploid cells in vitro (Ponten, 1975) 
Cell lines and routine culture conditions
The normal glial cell line U-787 CG was generated from adult human brain tissue as previously described (Ponten & Macintyre, 1968) . The establishment of the glioma line U-251 MG, derived from a spontaneously occurring human malignant glioma, has also been described . Cells were routinely grown in Eagle's minimum essential medium (Eagle, 1959) supplemented with 10% calf serum and antibiotics (100 i.u. of penicillin/ml, 50,ug of streptomycin/ml and 1.25,ug of amphotericin B/ml) (Squibb, Liding6, Sweden).
Subcultivation was carried out once or twice a week with 0.25 % (w/v) trypsin. Line U-251 MG was treated with 0.5 mM-EDTA in phosphate-buffered saline (137mM-NaCl, 2.7mM-KCl, 8.1 mMNa2HPO4, 1.5mM-KH2PO4, pH7.3) before trypsin digestion.
Incubation of cells with [35S] sulphate and [3'Hglucosamine Cells were treated with trypsin, pooled in routine Eagle's medium and seeded at a density of 4x 10 cells/55mm Nunc plastic dish. Sparse cultures were used 6-8 h later when cells had settled and spread. Dense cultures were obtained by growing the cells for 10-14 days under routine conditions. Normal cultures had then reached a cell density of about 1.2 x 106 cells/dish and showed a stationary growth phase (Ponten et al., 1969) . Growth of the glioma cell line also decreased at high cell densities, although not to the same extent as that of the normal cell line. Dense cultures ofglioma cells contained about 15 x 106 cells/dish (Westermark, 1973) . Incubations were started by replacing the medium with 5ml of F-10 medium (Ham, 1963) After incubation with radioactive precursors the medium, representing the extracellular pool, was collected and dishes were gently washed with 3 x 2ml of phosphate-buffered saline containing 100mg of CaCl2 and 100mg of MgSO4,7H20/litre. Cultures were then treated with trypsin (2ml of trypsin, 501ug/ ml in phosphate-buffered saline for 60min at 37'C). The trypsin fraction (pericellular pool) and the cell pellet after two washings with 2ml of phosphatebuffered saline (intracellular pool) were then collected. No decrease in cell number occurred during the trypsin incubation and all cells (>99%) remained viable, as tested by the Trypan Blue exclusion test. Alternatively, the cell layer was treated with EDTA (0.5mm in phosphate-buffered saline) for 60min at 37°C; remaining cells were detached by gentle pipetting. The dispersed cells were centrifuged (180g for 5min) and the supernatant was collected (EDTA fraction). EDTA was preferred to EGTA, since EDTA detached the glial cells much more efficiently than did EGTA. After treatment with EDTA for 60min, 5-10% of the cells were stained with Trypan Blue. After one 2ml wash in phosphate-1978 (Lindahl et al., 1973) in the presence of carrier chondroitin sulphate (100,ug/ml) (procedure 1) or hyaluronic acid (1 mg), chondroitin sulphate (2mg) and heparin (4mg) (procedure 2). The digests were then heat-inactivated at 100°C for 5mm.
In procedure 1, the macromolecular 35S-labelled material was recovered by gel chromatography in 1M-NaCl on a column (49cmx5cm or 90cmx2cm) of Sephadex G-50, and desalted by passage through a column of Sephadex G-50 in 10% (v/v) (Fig. 7) . This material was completely susceptible to leech hyaluronidase (Wasteson et al., 1973b) and showed glycosamine as the only hexosamine (Lohmander, 1971 were spotted on filter-paper strips and the strips treated with cetylpyridinium chloride in 0.3M-NaCl as described by Wasteson et al. (1973a (Fig. 1) . With short-time incubations a slight lag was revealed in the extracellular accumulation; however, the lag phase was consistently shorter than 1 h.
In contrast with the almost constant incorporation rate in normal glial cells, glioma cells showed a prolonged delay in the incorporation of 35S into the extracellular pool, with a continuous increase in the incorporation rate up to about 24h (Fig. 2) . Also the release of 35S-labelled glycosaminoglycans to the medium was less in glioma cultures than in normal cultures, with respect to both the c.p.m. incorporated per ,g of cellular protein (Table 2 ) and with respect to the relative amounts of 35S-labelled glycosaminoglycans present in the extracellular pool. After 1 h of incubation the extracellular pool of the glioma , supplemented with 10% calf serum) or in trypsin (50pg/ml) were treated as described in the Experimental section and precipitated on filter paper with cetylpyridinium chloride. The cetylpyridinium chloride-precipitable (non-susceptible) radioactivity is recorded for incubations with active (sample) and inactivated (control) (50,ug/ml) (Fig. 3) . A trypsin Vol. 172 4) S. The pool of glycosaminoglycans liberated by trypsin (pericellular pool) increased rapidly during the initial period of incubation, as shown in Fig. 1 (glial cells) and Fig. 2 (glioma cells) . The fact that the incorporation of I'S into glycosaminoglycans of the pericellular pools started promptly at zero time, without any detectable delay, seems to indicate that the delay in the extracellular accumulation of "S-labelled glycosaminoglycans was not due to diffusionrestricted access of the radioactive precursor. The accumulation of 35S-labelled glycosaminoglycans in the pericellular pool decreased with time, in both glial-and glioma-cell cultures, approaching a constant value at which the amount of "5S-labelled glycosaminoglycans entering and disappearing from the pool should be equal. Although the pericellular pool of glioma cultures constituted a larger proportion of the total incorporated radioactivity than that of the glial cultures, the absolute pool size (c.p.m./pg of protein) was smaller in glioma than in normal glial cultures (Table 2) .
Intracellular pool. The fraction of 35S-labelled glycosaminoglycans remaining cell-associated after trypsin digestion showed a low rate of incorporation in both glial and glioma cultures ( Figs. 1 and 2 ). After about 24h of incorporation a constant amount of 35S-labelled glycosaminoglycans was obtained. At 48h it constituted about 13% of the total cellassociated 35S-labelled glycosaminoglycans with no significant difference between the cell lines (Fig. 4) .
Subdivision of the pericellular pool
After incubation of normal glial cells with EDTA for 60min, the cells rounded up but only about 10 % of The EDTA-susceptible portion of 35S-labelled glycosaminoglycans wasconsiderably larger in glioma than in glial cultures, amounting to 31 % (26-40%) and 60% (51-67%) of cell-associated 35S-labelled glycosaminoglycans in sparse and dense cultures respectively (Fig. 4) . Incubation with phosphatebuffered saline alone liberated only 7% (5-14%); therefore, in contrast with the glial cells, the glioma cells showed a significant portion of specifically EDTA-susceptible 35S-labelled glycosaminoglycans.
After removal of cells with trypsin, no 35S-labelled glycosaminoglycans could be recovered from the plastic dish by subsequent treatment with alkali. In contrast, detachment of the cells with EDTA rather than trypsin left significant amounts of 35S-labelled glycosaminoglycans associated with the plastic surface (Fig. 4) . It is noteworthy that this fraction was both relatively (Fig. 4) and absolutely (Table 2) considerably greater in sparse cultures [glial 14% (range 7-16%); glioma 21 % (range 15-29%)] than in dense cultures (1-3 %). Subcultivation and continuous labelling with [35S]sulphate of both glial and glioma cultures over an extended period of time revealed that this pool increased with time in nonconfluent cultures, but remained constant after confluency was reached (Fig. 5 ). This finding, in conjunction with the data in Fig. 4 , indicates that no sulphated glycosaminoglycans are deposited into substrate-attached material in confluent cultures. At confluence, 35S-labelled substrate-attached material was 10% and 20% of total cell-associated 35S-labelled glycosaminoglycans in normal cultures and glioma cultures respectively.
Much of the 35S-labelled glycosaminoglycans remaining with the cell pellet after treatment with EDTA was solubilized by subsequent trypsin treatment (designated membrane fraction). As shown in Fig. 4 , glial-cell cultures showed a higher proportion of the membrane fraction than did the glioma-cell cultures. Since the absolute pool size (c.p.m./,ug of protein) of cell-associated 35S-labelled glycosaminoglycans was greater in glial cells, the total amount of 35S-labelled glycosaminoglycans in the membrane fraction was also greater (2-3 times) than in glioma-cell cultures. Slightly less 35S-labelled glycosaminoglycans was associated with the cells after a sequential treatment with EDTA and trypsin compared with trypsin treatment alone. Also, the combined treatment gave a somewhat lower total recovery of 35S-labelled glycosaminoglycans (6-21 % lower than the procedure involving trypsin only). This discrepancy may be due to losses during extra washings and centrifugations. In addition, intraVol. 172 cellular degradation of 3S-labelled glycosaminoglycans during the incubation with EDTA may be a contributing factor .
Nature of glycosaminoglycans of glial and glioma cultures
Isolation of glycosaminoglycans. After 48 h of incubation, labelled material from the various fractions was isolated by gel chromatography on Sephadex G-50 (Fig. 6) or by ion-exchange chromatography on DEAE-cellulose (Fig. 7) . When the amounts of 3"S-labelled glycosaminoglycans recovered from the individual compartments by any of the methods were compared with the original amounts of cetyl-pyridinium chloride-precipitable "5S-labelled glycosaminoglycans in the respective fractions, recoveries of 90-100% were found (results not shown). It is reasonable to believethat the recovery of 3H-labelled glycosaminoglycans was similar; this entity may not be readily assessed.
The separation of macromolecular 35S-labelled glycosaminoglycans from low-molecular-weight components on Sephadex G-50 was clear-cut in the extracellular and pericellular pools. However, the intracellular pools showed partial overlap between excluded and retarded material (Fig. 6) proteolysis (e.g. with papain). Its presence was not dependent on the cell density ofthe culture from which it was derived; it was demonstrable in sparse glioma but not sparse glial-cell cultures (results not shown). Fraction B was pooled separately from the excluded macromolecular 35S-labelled glycosaminoglycans (fraction A).
The 35S-labelled material retained on DEAEcellulose was eluted from the ion-exchanger along with and slightly after the reference sample of monosulphated chondroitin sulphate (Fig. 7) . Oversulphated species, i.e. carrying more than one sulphate residue per disaccharide unit, were present in both glial and glioma glycosaminoglycans. The pericellular glycosaminoglycans of glial cultures differed from those of glioma cultures in that a major part co-migrated with the chondroitin sulphate standard. DEAE-cellulose chromatography of [3H]-glucosamine-labelled material showed similar patterns and, in addition, a distinct component comigrating with standard hyaluronic acid. The latter was identified as hyaluronic acid as described in the Experimental section. No radioactivity was found at the elution position of standard heparin.
Identification ofglycosaminoglycans
Analysis of labelled glycosaminoglycans showed marked differences between glial and glioma cultures and between different compartments of individual cultures (Tables 3-5 The composition of 35S-labelled glycosaminoglycans was also determined by a simplified procedure, enabling analysis of culture fluids without prior isolation of glycosaminoglycans (Table 4) . The results were compared with those obtained by a standard procedure; good agreement between the two procedures was noted. In this experimental protocol the susceptibility of isolated 35S-labelled glycosaminoglycans (from dense cultures) to HNO2 and chondroitinases (see the Experimental section) was monitored by Sephadex G-50 chromatography; the relative amounts of heparan sulphate, dermatan sulphate and chondroitin sulphate were calculated according to the same principles as those used for the cetylpyridinium chloride procedure. It is noteworthy that the cetylpyridinium chloride technique, although much simpler and more rapid than the Sephadex G-50 method, is inevitably less informative with respect to the nature of the degradation products.
Normal glial cells. The extracellular pool of glial cultures showed a predominance of dermatan sulphate (about 55% of the pool), the remainder being made up by heparan sulphate and chondroitin sulphate in approximately equal proportions (about 20% each) (Tables 3 and 4) . A major proportion (about 80 %) of dermatan sulphate resisted treatment with chondroitinase AC, in that it showed an unchanged elution with the void volume on Sephadex G-50 chromatography (Fig. 8) . The remainder (about 20 %) was degraded to smaller fragments by chondroitinase AC, which thus represented relatively short blocks of iduronic acid-containing units. Hyaluronic acid was demonstrable in the extracellular pool but was only a minor component (10 % of the total glycosaminoglycans). Most of the hyaluronic acid (over 90%) of glial cell cultures was found in the extracellular pool (Table 5) .
The pericellular pool showed a typical composition of glycosaminoglycans, heparan sulphate being by far the most abundant species (75-80% of glycosaminoglycans). Dermatan sulphate and chondroitin sulphate were only minor components (about 10% each) and hyaluronic acid was present only in trace amounts.
The intracellular glycosaminoglycans resembled extracellular glycosaminoglycans, dermatan sulphate being the predominant species. A significant portion of the intracellular pool (17%) was not susceptible to the combined treatment with HNO2 and chondroitinase ABC (Table 3) .
Great differences were found between the compositions of the various subfractions of the pericellular pool. The EDTA fraction, like the extra-and intracellular pools, showed a predominance of dermatan sulphate, whereas the other subfractions were mainly composed of heparan sulphate ( Elution volume (ml) Fig. 8 . Gel chromatography on Sephadex G-50 of 3H-labelled galactosaminoglycans digested with chondroitinase AC 3H-labelled HNO2-resistant glycosaminoglycans from the extracellular pools of dense normal (a) and malignant (b) glial cell cultures were incubated with chondroitinase AC; the reaction mixtures were analysed by gel chromatography on a column (130cmx 1cm) of Sephadex G-50. The glial galactosaminoglycans yielded a higher ratio of macromolecular (elution volume 43-54ml) to intermediate size (elution volume 54-92ml) than did the glioma galactosaminoglycans. These two types of products were taken to represent glucuronic acid-poor and glucuronic acid-rich 3H-labelled dermatan sulphate respectively; see also the text and Glioma cells. All the compartments of glioma cultures contained a high proportion of hyaluronic acid, in contrast with the corresponding fractions of glial cultures (Table 3) . This was particularly striking in the extracellular pool, where about 90% of total glycosaminoglycans was hyaluronic acid. Among the sulphated glycosaminoglycans of the extracellular pool glioma and glial cultures displayed similar ratios of HN02-susceptible to chondroitinase ABC-susceptible glycosaminoglycans. However, in glioma cultures, the latter pool consisted mostly of chondroitin sulphate, whereas in glial cultures dermatan sulphate was predominant. The size distribution of the products obtained after treatment with chondroitinase AC showed that, not only were iduronic acid residues more scarce in glycosaminoglycans of the glioma than of the glial cells, but also blocks consisting of consecutive iduronic acid-containing disaccharides were shorter in glycosaminoglycans of glioma than of glial cells ( Fig. 8; Table 3 ). The pericellular pool consisted, apart from hyaluronic acid, mainly ofchondroitin sulphate and heparan sulphate; the predominance of heparan sulphate, typical of the pericellular pool of glial cultures, was not observed in the glioma-derived material (Tables 3 and 4) . The Vol. 172 intracellular pool, like the extracellular pool, showed chondroitin sulphate as the most abundant sulphated glycosaminoglycan; iduronic acid-containing disaccharides were rare (Table 3 ). The amount of sulphated glycosaminoglycans resisting the combined action of HNO2 and chondroitinase ABC was considerable (about 30%); as shown above the glial intracellular pool contained similarly a significant amount of resistant material. The identity of the resistant glycosaminoglycans was not resolved; however, a possible candidate would be N-acetylated heparan sulphate, which has previously been demonstrated in brain tissue (Margolis & Atherton, 1972) .
Material released by EDTA from the glioma cells showed a higher proportion of hyaluronic acid and a slightly lower proportion of heparan sulphate than the whole pericellular pool; the differences were, however, much smaller than for the normal cells (Tables 4 and 5 (Table 4) .
Discussion
A number of cultured cells of various origins have previously been shown to produce glycosaminoglycans. Previous observations in our laboratory indicated that cultured cells of glial origin manufactured both sulphated and non-sulphated glycosaminoglycans (Wasteson et al., 1973a,b; Westermark & Wasteson, 1973; Wasteson et al., 1975; Norling et al., 1976 (Margolis & Margolis, 1974) . Therefore the ability to produce this kind of substance may reflect a physiological property of glial cells rather than being a product of the conditions under which the cells were maintained in vitro. The functional significance of glycosaminoglycans in the nervous system is still unclear (Margolis & Margolis, 1977) .
In the present study [35S] Norling, B. Westermark & A. Wasteson, unpublished work) indicate that in glioma cultures most "S-labelled glycosaminoglycans found in the extracellular pool are retained at the cell surface for a considerably longer time than in normal glial cultures.
Glycosaminoglycans liberated from their cellassociated state by treatment with a dilute trypsin solution were considered as the pericellular pool. Since the use of trypsin for this purpose was introduced by Kraemer (1971a) it has been generally recognized and adapted in several investigations (e.g. Underhill & Keller, 1976) . However, by use of trypsin only, no distinction can be made between the intercellular matrix and the cell surface (plasma membrane) (Chiarugi et al., 1974; Kleinman et al., 1975) . Such a distinction is critical to the understanding of the role of cell-surface-associated glycosaminoglycans in cellular-interaction phenomena (Vaheri, 1978) , but, since methods for a direct analysis of glycosaminoglycans at different localities of a cell culture do not exist, we are left to operational definitions. In the present investigation attempts at a subdivision of cell-surface-associated glycosaminoglycans were performed by treatment of the cells with EDTA before trypsin treatment. The major drawback of EDTA treatment (Culp & Black, 1972) but also of treatment with collagenase (Kleinman et al., 1975) is decreased viability of the cells. However, the finding that EDTA liberated only slightly more glycosaminoglycans than treatment with phosphatebuffered saline indicates that a major part of glycosaminoglycans solubilized by EDTA was not due to a release from damaged cells. Rather, the EDTA fraction may consist of material from other compartments including entrapped material from the medium and matrix components. The fraction obtained from the EDTA-dispersed cells or from the intact glial-cell layer by treatment with trypsin was markedly homogeneous; 85 and 80% respectively consisted of heparan sulphate. Most of this heparan sulphate could be released from the cells by treatment with a heparan sulphate-degrading endoglycosidase (Culp et al., 1975) . This helps explain why much less radioactivity was incorporated into this fraction in dense cultures than in sparse cultures. The composition of substrateattached glycosaminoglycans of both glial and glioma cells (Tables 4 and 5 ) differed from that of 3T3 cells. Previous reports have also indicated higher amounts of substrate-attached glycosaminoglycans in non-transformed than in virus-transformed 3T3 cells (Terry & Culp, 1974; Roblin et al., 1975) . Analogous comparison between normal glial and malignant glioma cells, however, yielded opposite results. In conclusion, these findings indicate that the results obtained with the pseudo-normal 3T3 cell line are not generally applicable to human cells. Whether substrate-attached glycosaminoglycans play a role in density-dependent inhibition of growth, as has been suggested (Roblin et al., 1975; Culp, 1976) , remains unclear.
The high proportion of heparan sulphate in the pericellular pool of normal glial cells agrees with previous reports demonstrating the predominance of heparan sulphate on the cell surface of certain established rodent cell lines (Kraemer, 1971b) . Similarly, the pericellular sulphated glycosaminoglycans of human endothelial cells is almost exclusive heparan sulphate . In contrast, previous experiments with human skin fibroblasts have shown a significantly lower proportion of heparan sulphate (Malmstrom et al., 1975) . Pretreatment of skin fibroblasts with collagenase markedly increased the proportion of heparan sulphate in the remaining cell-surface fraction (recovered by trypsin) (Kleinman et al., 1975) ; this finding clearly indicates that admixture of deposited intercellular material distorts the estimated proportions of individual glycosaminoglycans in the cellsurface fraction. In glioma-cell cultures hyaluronic acid, rather than heparan sulphate, was the predominant species among pericellular glycosaminoglycans (Table 3) . Similarly, Vannucchi & Chiarugi (1977) (Underhill & Keller, 1975; Cohn et al., 1976) . The definition of chondroitin sulphate and dermatan sulphate used in the present investigation was based on the observed susceptibility of glycosaminoglycans to treatment with chondroitinases, and hence related to the relative content of glucuronic acid and iduronic acid (Yamagata et al., 1968) . Since glucuronic acid-containing units are known to form co-polymericchains with iduronic acidcontaining units (Fransson, 1970 ) the estimated amounts of dermatan sulphate represent minimum values. The underestimation of dermatan sulphate tends to be greater by the cetylpyridinium chloride procedure than by the gel-chromatography analysis, since the former procedure would not detect small iduronic acid-containing oligosaccharides among the chondroitinase-digestion products. The gliomaderived dermatan sulphate showed a higher proportion of short iduronic acid-containing sequences; these components were formed from co-polymeric chains with an unknown ratio of glucuronic acid to iduronic acid. However, irrespective of the copolymeric composition, the glioma cells formed less iduronic acid-containing repeating units than did the glial cells. It is thus possible that the glioma cells are deficient in the enzymic complex dealing with the conversion of glucuronic acid into iduronic acid in the polysaccharide chain.
The malignant glioma cells produced far more hyaluronic acid, but less sulphated glycosaminoglycans, than did the normal glial cells (Tables 2  and 5 ). The significance of this finding is not clear. If the observed differences are representative of conditions in vivo, it is reasonable to conclude that the tumour cells surround themselves with and grow in an intercellular matrix that is quite different from that of normal glial cells. In some systems of virus-transformed cells, the transformed state has similarly been shown to be associated with an increase in hyaluronic acid production (Ishimoto et al., 1966; Satoh et al., 1973) or a decrease in the production of sulphated glycosaminoglycans (Underhill & Keller, 1975) , as compared with the nontransformed state. However, these phenomena are probably not universal (Hamerman et al., 1965; Cohn et al., 1976 Comparison between glial and glioma cultures indicated several differences with respect to amounts and proportions of various types of glycosaminoglycans in the different culture compartments. Since cell density had little influence on the parameters under study (Tables 2 and 4) , it may be concluded that the observed differences between glial and glioma cultures were due to the malignant transformation itself rather than to differences in cell density or growth state. With the 3T3 cell system, other authors (Cohn et al., 1976; Vannucchi & Chiarugi, 1977) reached an opposite conclusion, i.e. that cell density and possibly density-dependent inhibition of growth, but not viral transformation, are major factors controlling glycosaminoglycan metabolism.
